An update from Dr. Mitchell Cairo on his research and treatments, emailed to David on December 16, 2017:
The Marisa Fund has been responsible for supporting a new clinical research trial in the adolescents and young adults with Hodgkin Lymphoma. The primary aim is to investigate the use of targeted therapy using antibodies and antibody-conjugates and remove toxic chemotherapy and radiation from the treatment to maintain high cure rates and decrease late effects. We have treated 27 patients to date with 100% complete remission and disease free survival and no acute or late effects to date!
Thank you to everyone for the support! It is because of our efforts that research like this can take place.